vs

Side-by-side financial comparison of InspireMD, Inc. (NSPR) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.

cbdMD, Inc. is the larger business by last-quarter revenue ($5.0M vs $3.1M, roughly 1.6× InspireMD, Inc.). On growth, InspireMD, Inc. posted the faster year-over-year revenue change (61.6% vs -1.9%). cbdMD, Inc. produced more free cash flow last quarter ($-977.3K vs $-9.7M). Over the past eight quarters, InspireMD, Inc.'s revenue compounded faster (44.4% CAGR vs 7.1%).

InspireMD Inc. is a global medical device company specializing in innovative interventional cardiology and neurovascular solutions. Its flagship MGuard embolic protection stent line is engineered to reduce complications during vascular procedures, serving clinical customers across North America, Europe, and key Asia-Pacific markets, with a core focus on improving patient outcomes for acute coronary syndrome and stroke care.

cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.

NSPR vs YCBD — Head-to-Head

Bigger by revenue
YCBD
YCBD
1.6× larger
YCBD
$5.0M
$3.1M
NSPR
Growing faster (revenue YoY)
NSPR
NSPR
+63.5% gap
NSPR
61.6%
-1.9%
YCBD
More free cash flow
YCBD
YCBD
$8.8M more FCF
YCBD
$-977.3K
$-9.7M
NSPR
Faster 2-yr revenue CAGR
NSPR
NSPR
Annualised
NSPR
44.4%
7.1%
YCBD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NSPR
NSPR
YCBD
YCBD
Revenue
$3.1M
$5.0M
Net Profit
$-283.1K
Gross Margin
37.5%
59.8%
Operating Margin
-383.7%
-5.7%
Net Margin
-5.6%
Revenue YoY
61.6%
-1.9%
Net Profit YoY
-1975.7%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NSPR
NSPR
YCBD
YCBD
Q4 25
$3.1M
$5.0M
Q3 25
$2.5M
$4.7M
Q2 25
$1.8M
$4.6M
Q1 25
$1.5M
$4.7M
Q4 24
$1.9M
$5.1M
Q3 24
$1.8M
$4.6M
Q2 24
$1.7M
$5.2M
Q1 24
$1.5M
$4.4M
Net Profit
NSPR
NSPR
YCBD
YCBD
Q4 25
$-283.1K
Q3 25
$-12.7M
$-680.0K
Q2 25
$-13.2M
$-895.3K
Q1 25
$-11.2M
$-480.8K
Q4 24
$15.1K
Q3 24
$-7.9M
$-152.8K
Q2 24
$-7.9M
$459.7K
Q1 24
$-7.0M
$-3.0M
Gross Margin
NSPR
NSPR
YCBD
YCBD
Q4 25
37.5%
59.8%
Q3 25
34.2%
58.8%
Q2 25
17.6%
61.5%
Q1 25
19.1%
62.3%
Q4 24
24.1%
66.5%
Q3 24
22.9%
53.9%
Q2 24
19.0%
65.8%
Q1 24
19.3%
59.0%
Operating Margin
NSPR
NSPR
YCBD
YCBD
Q4 25
-383.7%
-5.7%
Q3 25
-517.3%
-14.5%
Q2 25
-732.2%
-19.6%
Q1 25
-749.5%
-10.2%
Q4 24
-480.6%
-1.7%
Q3 24
-467.5%
-6.9%
Q2 24
-475.0%
-7.4%
Q1 24
-490.7%
-35.4%
Net Margin
NSPR
NSPR
YCBD
YCBD
Q4 25
-5.6%
Q3 25
-503.7%
-14.4%
Q2 25
-739.7%
-19.4%
Q1 25
-730.3%
-10.1%
Q4 24
0.3%
Q3 24
-435.9%
-3.4%
Q2 24
-454.8%
8.9%
Q1 24
-465.4%
-68.8%
EPS (diluted)
NSPR
NSPR
YCBD
YCBD
Q4 25
$-0.11
Q3 25
$-0.17
Q2 25
$-0.26
Q1 25
$-0.22
Q4 24
$-0.17
Q3 24
$-0.16
Q2 24
$-0.22
$-0.15
Q1 24
$-0.21
$-1.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NSPR
NSPR
YCBD
YCBD
Cash + ST InvestmentsLiquidity on hand
$54.2M
$3.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$55.2M
$9.0M
Total Assets
$69.4M
$11.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NSPR
NSPR
YCBD
YCBD
Q4 25
$54.2M
$3.4M
Q3 25
$63.4M
$2.3M
Q2 25
$19.4M
$1.1M
Q1 25
$26.1M
$1.8M
Q4 24
$34.6M
$2.0M
Q3 24
$40.4M
$2.5M
Q2 24
$47.2M
$2.4M
Q1 24
$34.0M
$2.1M
Stockholders' Equity
NSPR
NSPR
YCBD
YCBD
Q4 25
$55.2M
$9.0M
Q3 25
$64.1M
$7.2M
Q2 25
$20.2M
$6.1M
Q1 25
$28.3M
$665.8K
Q4 24
$36.1M
$1.8M
Q3 24
$41.4M
$2.0M
Q2 24
$46.8M
$3.0M
Q1 24
$35.1M
$3.1M
Total Assets
NSPR
NSPR
YCBD
YCBD
Q4 25
$69.4M
$11.8M
Q3 25
$78.5M
$10.4M
Q2 25
$33.3M
$9.9M
Q1 25
$38.7M
$10.9M
Q4 24
$46.8M
$11.5M
Q3 24
$50.5M
$10.6M
Q2 24
$55.7M
$13.8M
Q1 24
$42.0M
$14.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NSPR
NSPR
YCBD
YCBD
Operating Cash FlowLast quarter
$-9.3M
$-812.5K
Free Cash FlowOCF − Capex
$-9.7M
$-977.3K
FCF MarginFCF / Revenue
-309.4%
-19.5%
Capex IntensityCapex / Revenue
12.6%
3.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-36.8M
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NSPR
NSPR
YCBD
YCBD
Q4 25
$-9.3M
$-812.5K
Q3 25
$-8.6M
$-240.7K
Q2 25
$-8.3M
$-704.2K
Q1 25
$-8.8M
$-189.5K
Q4 24
$-6.8M
$-317.9K
Q3 24
$-5.7M
$167.4K
Q2 24
$-4.4M
$289.8K
Q1 24
$-5.1M
$-704.1K
Free Cash Flow
NSPR
NSPR
YCBD
YCBD
Q4 25
$-9.7M
$-977.3K
Q3 25
$-9.0M
$-243.6K
Q2 25
$-8.9M
$-705.7K
Q1 25
$-9.2M
$-205.0K
Q4 24
$-7.1M
$-482.3K
Q3 24
$-6.1M
$157.4K
Q2 24
$-4.8M
Q1 24
$-5.3M
$-708.7K
FCF Margin
NSPR
NSPR
YCBD
YCBD
Q4 25
-309.4%
-19.5%
Q3 25
-355.2%
-5.2%
Q2 25
-501.1%
-15.3%
Q1 25
-598.5%
-4.3%
Q4 24
-362.3%
-9.4%
Q3 24
-338.2%
3.5%
Q2 24
-277.7%
Q1 24
-348.0%
-16.2%
Capex Intensity
NSPR
NSPR
YCBD
YCBD
Q4 25
12.6%
3.3%
Q3 25
13.0%
0.1%
Q2 25
32.4%
0.0%
Q1 25
23.5%
0.3%
Q4 24
16.0%
3.2%
Q3 24
23.3%
0.2%
Q2 24
27.3%
0.0%
Q1 24
12.9%
0.1%
Cash Conversion
NSPR
NSPR
YCBD
YCBD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-21.06×
Q3 24
Q2 24
0.63×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NSPR
NSPR

Other$1.7M55%
US$1.4M45%

YCBD
YCBD

Sales Channel Directly To Consumer$3.6M72%
Sales Channel Through Intermediary$1.4M28%

Related Comparisons